Purine P2Y12 inhibitors act to inhibit platelet aggregation by inhibiting adenosine diphosphate P2Y12 receptors [12], and increased cancer mortality has been reported in patients with long-term use of these drugs [11,12,13,14,15]. The gene discussed is P2RY12; the disease is cancer.